Weekly Analysts’ Ratings Updates for CRISPR Therapeutics (CRSP)

A number of firms have modified their ratings and price targets on shares of CRISPR Therapeutics (NASDAQ: CRSP) recently:

• 8/31/2026 – CRISPR Therapeutics had its “buy” rating reaffirmed by HC Wainwright.
• 8/31/2026 – CRISPR Therapeutics had its “market outperform” rating reaffirmed by Citizens Jmp. They now have a $80.00 price target on the stock.
• 8/31/2026 – CRISPR Therapeutics had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $82.00 price target on the stock.
• 8/25/2026 – CRISPR Therapeutics had its “market outperform” rating reaffirmed by Citigroup Inc..
• 8/25/2026 – CRISPR Therapeutics had its “market outperform” rating reaffirmed by Citizens Jmp. They now have a $80.00 price target on the stock.
• 8/8/2026 – CRISPR Therapeutics was upgraded by Wall Street Zen from “sell” to “hold”.
• 8/6/2026 – CRISPR Therapeutics had its “neutral” rating reaffirmed by The Goldman Sachs Group, Inc.. They now have a $55.00 price target on the stock.
• 8/4/2026 – CRISPR Therapeutics had its price target raised by Citigroup Inc. from $82.00 to $88.00. They now have a “buy” rating on the stock.
• 7/22/2026 – CRISPR Therapeutics had its “market outperform” rating reaffirmed by Citigroup Inc..
• 7/17/2026 – CRISPR Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 7/8/2026 – CRISPR Therapeutics had its “buy” rating reaffirmed by HC Wainwright. They now have a $80.00 price target on the stock.
• 7/6/2026 – CRISPR Therapeutics had its “market outperform” rating reaffirmed by Citizens Jmp. They now have a $80.00 price target on the stock.
• 7/5/2026 – CRISPR Therapeutics was downgraded by Wall Street Zen from “hold” to “sell”.

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.